SB 202190: Selective p38 MAP Kinase Inhibitor for Research

Executive Summary: SB202190 (FHPI) is a highly selective, cell-permeable inhibitor of p38α and p38β MAP kinases, exhibiting IC50 values of 50 nM and 100 nM respectively (product information). It acts by competitively binding the ATP pocket, suppressing kinase activity and downstream phosphorylation events. This compound is widely adopted in inflammation research, apoptosis assays, and cancer therapeutics research, with validated use in both in vitro and in vivo models. Animal studies demonstrate neuroprotective effects, including reduced neuronal apoptosis and improved spatial memory. SB202190's solubility profile and storage protocols support its versatility in preclinical workflows.

Biological Rationale

p38 MAP kinases are central regulators of cellular responses to stress, inflammation, and cytokine signaling. Dysregulation of the MAPK pathway is implicated in various diseases, including cancer, cardiovascular disease, and neurodegeneration. Targeting p38α and p38β isoforms enables researchers to modulate key events such as cytokine expression, apoptosis, and cellular proliferation. According to Konstantinidis et al., regulated cell death pathways, including apoptosis and necrosis, underpin the pathology of cardiovascular and oncologic diseases (DOI link). By pharmacologically inhibiting p38 MAPKs, SB202190 provides a precise tool to interrogate these mechanisms in disease models.

Mechanism of Action of SB202190 (FHPI)

SB202190 is a pyridinyl imidazole derivative that acts as an ATP-competitive kinase inhibitor. It selectively targets p38α (IC50 = 50 nM) and p38β (IC50 = 100 nM) by binding the ATP-binding pocket, with a dissociation constant (Kd) of 38 nM for p38 MAPK (product information). This binding event blocks the kinase's ability to phosphorylate downstream substrates, including proteins involved in pro-inflammatory signaling and apoptosis. As a result, SB202190 suppresses the production of inflammatory cytokines and promotes apoptosis in certain cancer models. The compound's selectivity is confirmed by minimal activity against other MAPK family members, such as ERK and JNK, at concentrations effective for p38 inhibition (see further discussion).

Evidence & Benchmarks

• SB202190 inhibits p38α MAPK activity with an IC50 of 50 nM and p38β with 100 nM, as confirmed in kinase assays (product information).
• It suppresses phosphorylation of downstream substrates, reducing pro-inflammatory cytokine expression in cellular models (internal review).
• In apoptosis assays, SB202190 promotes cell death in cancer cell lines by blocking survival signals downstream of p38 MAPK (DOI link).
• Animal studies show that intracerebroventricular injection of SB202190 in rats reduces hippocampal neuronal apoptosis and improves spatial learning and memory (product page).
• Solubility benchmarks: SB202190 is insoluble in water, but dissolves in DMSO (≥57.7 mg/mL) and ethanol (≥22.47 mg/mL) at room temperature (specification).

This article expands on the detailed selectivity and workflow integration of SB202190, offering practical storage and assay conditions not covered in previous reviews which focus primarily on mechanistic selectivity.

Applications, Limits & Misconceptions

SB202190 is a standard tool in inflammation research, enabling precise dissection of the MAPK signaling pathway. Its use is validated in cell culture (5 μM, 72 h) and animal models, such as vascular dementia and neuroprotection studies. In cancer therapeutics research, SB202190 is used to sensitize tumor cells to apoptosis by interfering with survival signaling. The molecule is also applied in apoptosis assays and in models examining memory-associated signaling. Notably, SB202190 has been leveraged in recent work to analyze Treg dynamics and tumor-immune interactions in colorectal cancer, highlighting its immunomodulatory potential (see comparative CRC study).

Common Pitfalls or Misconceptions

• SB202190 does not inhibit JNK or ERK kinases at concentrations effective for p38 inhibition; lack of effect should not be attributed to poor solubility or degradation.
• It is not water-soluble; attempts to dissolve in aqueous buffers without DMSO or ethanol will fail.
• Long-term storage of prepared solutions (>10 mM in DMSO) above -20°C reduces potency; solutions should not be stored at room temperature.
• SB202190 is not a pan-kinase inhibitor; its effects are not generalizable to all MAPK pathways.
• In vivo effects, such as neuroprotection, may depend on administration route and dosage; systemic delivery may not reproduce intracerebroventricular results.

Workflow Integration & Parameters

• Stock solution preparation: Dissolve SB202190 in DMSO at concentrations >10 mM; store aliquots below -20°C for up to several months (specification).
• Working concentration (cell culture): 5 μM, applied for up to 72 hours to model chronic pathway inhibition.
• Solubility: Achieves ≥57.7 mg/mL in DMSO and ≥22.47 mg/mL in ethanol at room temperature.
• In vivo (rat hippocampus): Intracerebroventricular administration reduces neuronal apoptosis and enhances spatial learning (product documentation).
• Storage: Store solid compound at -20°C; avoid repeated freeze-thaw cycles of solutions.

For detailed protocol guidance in p38 MAPK pathway dissection, see also SB202190 in translational research, which emphasizes experimental optimization for apoptosis and neuroprotection. This article extends that work by providing practical solubility and workflow parameters for bench scientists.

Conclusion & Outlook

SB202190 (FHPI), supplied by APExBIO, is a validated, selective p38 MAP kinase inhibitor with high potency and robust workflow compatibility. Its capacity to modulate inflammation and apoptosis, coupled with well-characterized solubility and storage properties, positions it as a gold standard in MAPK pathway research. Evidence from both in vitro and animal models supports its continued use in inflammation, cancer, and neuroprotection studies (DOI link). As research advances, SB202190 will remain a cornerstone tool for dissecting p38 MAPK-associated disease mechanisms, with careful adherence to established protocols ensuring reproducibility and reliability.